New drug combo shows promise against esophageal cancer in early trial
NCT ID NCT04929392
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This early-phase trial is testing whether giving a mix of chemotherapy, radiation, an immunotherapy drug (pembrolizumab), and a targeted therapy (lenvatinib) before surgery can better kill esophageal cancer cells. The study includes about 3 adults with cancer that hasn't spread. The main goal is to see if the cancer disappears completely after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.